Medical technology company EndoChoice has obtained the US Food and Drug Administration (FDA) approval and introduced its Lumos with Adaptive Matrix Imaging.
Lumos is based on the Adaptive Matrix Imaging which examines and specifically highlights the vascularity, surface texture, and colour of abnormal tissue.
It informs the physicians to aid in their detection of abnormalities during gastrointestinal procedures.
Lumos facilitates a seamless detection of the affected tissue which is done by toggling between two settings, the first setting has been designed to selectively highlight the tissue and the second setting enables an in-depth examination following the identification of the suspect tissue.
Radboud University Medical Center, Nijmegen, The Netherlands endoscopic gastrointestinal oncology professor Peter Siersema said: "Other image processing technologies alter the image, which can be distracting.
“With Lumos, only anatomy that has certain textures, vascularity or abnormal anatomy is enhanced, allowing me to keep my focus on potentially diseased tissue."
A recently carried out unpublished clinical study has demonstrated the efficacy of Lumos with Adaptive Matrix Imaging in enhancing lesions with pit patterns, as well as assisting the detection of tissue abnormalities throughout the procedure.
The introduction of Lumos will add to the company’s existing portfolio of Generation 3 Fuse Full Spectrum Endoscopy System.
The Fuse is a flexible endoscopy system offering a panoramic 330° view for the physicians during the upper and lower endoscopies.
The Fuse gastroscope offers a 245° view during upper endoscopies.
The wide-angled view is offered by the Fuse colonoscope as it uses three cameras with two on the gastroscope.
Image: Lumos with Adaptive Matrix Imaging. Photo: courtesy of EndoChoice, Inc.